Intranasal Drug Delivery

Global Intranasal Drug Delivery Market to Reach US$93.3 Billion by 2030

The global market for Intranasal Drug Delivery estimated at US$63.1 Billion in the year 2024, is expected to reach US$93.3 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Liquid Delivery Devices, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$38.2 Billion by the end of the analysis period. Growth in the Powder Delivery Devices segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$26.2 Billion While China is Forecast to Grow at 9.1% CAGR

The Intranasal Drug Delivery market in the U.S. is estimated at US$26.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.2 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.2% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Global Intranasal Drug Delivery Market - Key Trends and Drivers Summarized

Intranasal drug delivery refers to the administration of medications through the nasal cavity, offering a non-invasive and efficient route for drug absorption. This method leverages the rich vascularization and large surface area of the nasal mucosa, enabling rapid onset of action and enhanced bioavailability compared to other non-invasive routes. Intranasal delivery systems are utilized for a variety of drugs, including those for pain management, neurological disorders, and vaccinations. The technology behind these systems includes metered-dose nasal sprays, nasal gels, and powder formulations, each designed to optimize drug absorption and minimize systemic side effects.

The application of intranasal drug delivery spans several therapeutic areas, making it a versatile tool in modern medicine. It is particularly beneficial in emergency situations where rapid drug action is critical, such as with naloxone for opioid overdoses or epinephrine for anaphylactic reactions. Additionally, intranasal delivery is increasingly used for chronic conditions like migraines and hormonal therapies, where it offers a convenient and non-invasive alternative to injections. The ability to bypass the gastrointestinal tract and first-pass metabolism in the liver also makes this route advantageous for drugs that are poorly absorbed orally or extensively metabolized.

The growth in the intranasal drug delivery market is driven by several factors, including advancements in delivery technologies, increasing prevalence of chronic and acute conditions requiring rapid intervention, and a growing preference for non-invasive administration methods among patients and healthcare providers. Technological innovations, such as improved formulations and novel delivery devices, enhance drug stability and absorption, expanding the range of treatable conditions. Additionally, demographic trends such as aging populations and rising incidences of conditions like Alzheimer`s disease and Parkinson`s disease fuel demand for more effective drug delivery systems. Consumer behavior shifts towards self-administration and home care, coupled with healthcare cost containment strategies, further propel market expansion. The development of intranasal vaccines, particularly highlighted by the COVID-19 pandemic, also underscores the critical role of this delivery method in global health strategies.

SCOPE OF STUDY:

The report analyzes the Intranasal Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Liquid Delivery Devices, Powder Delivery Devices, Pressurized Metered Dose Inhalers, Other Product Types); Application (Respiratory Disorders, Neurological Disorders, Pain Management, Other Applications)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 77 Featured) -

• Acorda Therapeutics, Inc.
• Ferring Pharmaceuticals Inc
• Bespak Europe Ltd.
• Breckenridge Pharmaceutical, Inc.
• Janssen Global Services LLC
• Hikma Pharmaceuticals PLC
• Biologische Heilmittel Heel GmbH
• Evoke Pharma, Inc.
• KemPharm, Inc.
• Impel NeuroPharma
• Actiza Pharmaceutical Pvt., Ltd.
• Covis Pharma
• H&T Presspart Manufacturing Ltd.
• Biomedica International
• Alchemy Pharmatech Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.